Eledon Pharmaceuticals Inc (ELDN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $178.63M
Last updated: Nov 17, 2026 at 4:15 PM ET
Eledon Pharmaceuticals Inc (ELDN) Stock Chart
Eledon Pharmaceuticals (ELDN) has a latest price of $1.98 on Nov 17, 2026, 55.9% below its 52-week high of $4.49. Its price rose 12.5% over the past 12 months. The month-end price fell 98.4% over the 10 years through Oct 2026, a compound annual decline of 34.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $178.08 in Oct 2016 and its lowest $1.15 in Nov 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ELDN with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ELDN.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 44.2%, and over 6 months it fell 44.7%. The month-end price rose 77.6% over the 3 years through Oct 2026, a compound annual rate of 21.1%.
| Period | Change |
|---|---|
| 1 month | -8.3% |
| 3 months | -44.2% |
| 6 months | -44.7% |
| 12 months | +12.5% |
| 12 months, with dividends | +12.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +77.6% | +21.1% |
| 5 years | -44.6% | -11.1% |
| 10 years | -98.4% | -34.1% |
Price by Year
Its best calendar year was 2024, when the price rose 128.9%, and its weakest was 2021, when it fell 71.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.77 | +83.4% |
| 2025 | $1.51 | -63.3% |
| 2024 | $4.12 | +128.9% |
| 2023 | $1.80 | -21.1% |
| 2022 | $2.28 | -48.3% |
| 2021 | $4.41 | -71.4% |
| 2020 | $15.40 | +47.6% |
| 2019 | $10.43 | -63.7% |
| 2018 | $28.78 | -60.6% |
| 2017 | $73.02 | -53.9% |
Trading Range
The price is 21.4% below its 50-day average of $2.52 and 36.6% below its 200-day average of $3.12.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.98 | |
| 52-week high | $4.49 | -55.9% |
| 52-week low | $1.35 | +46.7% |
| 50-day average | $2.52 | -21.4% |
| 200-day average | $3.12 | -36.6% |
Price Risk
Over 3 years, its largest fall from a peak was 73.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.84 |
| Largest fall, 1 year | -53.2% |
| Largest fall, 3 years | -73.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ELDN
What is ELDN's 1-year price change?
Eledon Pharmaceuticals's price rose 12.5% over the past 12 months. With dividends included, the 12-month total return was 12.5%.
What is ELDN's 5-year price change?
Eledon Pharmaceuticals's month-end price fell 44.6% over the 5 years through Oct 2026, a compound annual decline of 11.1%. These figures leave out dividends.
What is ELDN's 52-week high and low?
Eledon Pharmaceuticals's 52-week high is $4.49 and its 52-week low is $1.35. Its latest price of $1.98 on Nov 17, 2026 is 55.9% below the high.
What is ELDN's beta?
Eledon Pharmaceuticals's 1-year beta against the S&P 500 is 1.84, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 53.2%.
Is the ELDN chart free?
Yes. Advanced Charting for ELDN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ELDN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors